Prokidney Corp. (PROK) — SEC Filings
Prokidney Corp. (PROK) — 36 SEC filings. Latest: 10-Q (Nov 10, 2025). Includes 18 8-K, 6 10-Q, 4 SC 13G/A.
View Prokidney Corp. on SEC EDGAR
Overview
Prokidney Corp. (PROK) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 10, 2025: PROKIDNEY CORP. reported a net loss of $16.469 million for the three months ended September 30, 2025, an improvement from a net loss of $17.910 million in the same period of 2024. For the nine months ended September 30, 2025, the net loss available to Class A common stockholders increased to $49.755
Sentiment Summary
Across 36 filings, the sentiment breakdown is: 2 bearish, 34 neutral. The dominant filing sentiment for Prokidney Corp. is neutral.
Filing Type Overview
Prokidney Corp. (PROK) has filed 6 10-Q, 18 8-K, 2 SC 13G, 4 SC 13G/A, 3 SC 13D/A, 1 DEF 14A, 1 10-K, 1 8-K/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (36)
Risk Profile
Risk Assessment: Of PROK's 28 recent filings, 2 were flagged as high-risk, 14 as medium-risk, and 12 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $668K |
| Net Income | -$49.755M |
| EPS | -$0.38 |
| Debt-to-Equity | N/A |
| Cash Position | $95.323M |
| Operating Margin | N/A |
| Total Assets | $351.608M |
| Total Debt | $33.270M |
Key Executives
- Carlos Slim Domit
- Carlos Slim Helu
- PABLO LEGORRETA
- Bruce Culleton, M.D.
- Dr. Karen Smith
- Dr. Robert Johnson
Industry Context
ProKidney Corp. operates in the biotechnology and regenerative medicine sector, focusing on developing therapies for kidney disease. This industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Success often depends on groundbreaking scientific innovation and successful clinical trials, with a competitive landscape featuring both established pharmaceutical giants and emerging biotech firms.
Top Tags
corporate-action (6) · corporate-governance (5) · biotech (5) · financials (4) · 10-Q (4) · Biotechnology (3) · material-definitive-agreement (3) · material-agreement (3) · disclosure (3) · sec-filing (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net loss (Q3 2025) | $16.469M | Improved from $17.910M in Q3 2024 |
| Net loss (9 months 2025) | $49.755M | Increased from $39.908M in 9 months 2024 |
| Revenue (9 months 2025) | $668K | Compared to $0 in 9 months 2024 |
| R&D expenses (9 months 2025) | $79.966M | Decreased from $87.887M in 9 months 2024 |
| Cash and cash equivalents (Sept 30, 2025) | $95.323M | Down from $99.120M at Dec 31, 2024 |
| Marketable securities (Sept 30, 2025) | $176.402M | Down from $259.172M at Dec 31, 2024 |
| Total current assets (Sept 30, 2025) | $299.989M | Down from $395.884M at Dec 31, 2024 |
| Class A common stock shares outstanding (Nov 10, 2025) | 141,545,448 | Increased from 128,054,417 at Dec 31, 2024 |
| Net loss per share (9 months 2025) | $0.38 | Improved from $0.45 in 9 months 2024 |
| Net cash used in operating activities (9 months 2025) | $87.604M | Reduced from $102.180M in 9 months 2024 |
| SEC File Number | 001-40560 | Identifies the company's filing history with the SEC. |
| IRS Employer Identification No. | 98-1586514 | Unique tax identification number for the company. |
| Net loss attributable to Class A common stockholders | $16.552M | for the three months ended June 30, 2025, increased from $12.506M in 2024 |
| Revenue | $221K | for the three months ended June 30, 2025, up from $0 in 2024 |
| Research and development expenses | $53.145M | for the six months ended June 30, 2025, decreased from $56.637M in 2024 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Prokidney Corp. (PROK)?
Prokidney Corp. has 36 recent SEC filings from Jan 2024 to Nov 2025, including 18 8-K, 6 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PROK filings?
Across 36 filings, the sentiment breakdown is: 2 bearish, 34 neutral. The dominant sentiment is neutral.
Where can I find Prokidney Corp. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Prokidney Corp. (PROK) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Prokidney Corp.?
Key financial highlights from Prokidney Corp.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PROK?
The investment thesis for PROK includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Prokidney Corp.?
Key executives identified across Prokidney Corp.'s filings include Carlos Slim Domit, Carlos Slim Helu, PABLO LEGORRETA, Bruce Culleton, M.D., Dr. Karen Smith and 1 others.
What are the main risk factors for Prokidney Corp. stock?
Of PROK's 28 assessed filings, 2 were flagged high-risk, 14 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Prokidney Corp.?
Forward guidance and predictions for Prokidney Corp. are extracted from SEC filings as they are enriched.